Evidence map›Paper›PMID 42011880›Full record

SynthesisEuropean heart journal. Cardiovascular pharmacotherapy2026

Monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways in eosinophilic myocarditis: a single-centre experience and systematic literature review.

Andrea S Giordani, Caterina Menghi, Anna Baritussio, Federico Scognamiglio, Cristina Vicenzetto, Federica Davanzo, Luca Iorio, Renzo Marcolongo, Monica De Gaspari, Stefania Rizzo and 3 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrea S GiordaniCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Caterina MenghiCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Anna BaritussioCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Federico ScognamiglioCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Cristina VicenzettoCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Federica DavanzoRheumatology, Department of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Luca IorioRheumatology, Department of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Renzo MarcolongoCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Monica De GaspariCardiovascular Pathology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Stefania RizzoCardiovascular Pathology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
Cristina BassoCardiovascular Pathology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.ORCID 0000-0002-0195-9753
Roberto PadoanRheumatology, Department of Medicine, University of Padova, Via Giustiniani 2, Padova 35128, Italy.ORCID 0000-0002-2356-375X
Alida L P CaforioCardiology and Cardioimmunology Laboratory, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.ORCID 0000-0002-4901-5655

Funding

'Enhancement and strengthening of biomedical research in the NHSEU-NRRPEuropean Union-Next generation
6 · The paper itself

Abstract

aimsEosinophilic myocarditis (EM) is a rare inflammatory heart disease often associated with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome. While anti-IL-5/5R and anti-IL-4/13 monoclonal antibodies (mAbs) efficacy in systemic eosinophilic diseases is established, data on EM are lacking. We aimed to (1) characterize a single-centre cohort of EM patients treated with mepolizumab, benralizumab, or dupilumab in combination with glucocorticoids and/or immunosuppressants; (2) systematically review published cases, comparing them with a contemporary cohort; and (3) evaluate myocardial response and safety of mAbs in EM, in comparison with a historical cohort treated without mAbs at our centre. METHODS AND

resultsThirty-seven EM patients were included (19 from a contemporary cohort, 18 from the literature; 51% male; median age 47 years). Biologic treatments were mepolizumab (81%), benralizumab (14%), and dupilumab (5%). Median time to mAb initiation was 2.5 months; treatment duration 24 months. No EM relapses, deaths, or heart transplantations occurred. Glucocorticoids were tapered and withdrawn in 89% of cases, with no mAb discontinuations due to adverse events. In the contemporary cohort, mAb therapy was associated with improved LVEF (47%-55%, P = 0.004), TnI normalization (95%-12%, P < 0.001), and eosinophil reduction (95%-11%, P < 0.001). Compared with EM patients managed with conventional immunosuppressants alone, the mAb group had no myocarditis relapses (0% vs. 25%) and lower follow-up eosinophil counts (0.04 × 109/L vs. 0.85 × 109/L).

conclusionIn EM within eosinophilic disease, anti-IL-5/5R and anti-IL-4/13 mAbs showed steroid-sparing effects and favourable safety, suggesting potential benefit for disease control.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedEosinophiliaInterleukin-4Interleukin-5MyocarditisReceptors, Interleukin-5AdultDrug Therapy, CombinationFemaleGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedbenralizumabdupilumabGlucocorticoidsIL5 protein, humanImmunosuppressive AgentsInterleukin-4Interleukin-5mepolizumabReceptors, Interleukin-5Eosinophilic granulomatosis with polyangiitisEosinophilic myocarditisHypereosinophilic syndromeMonoclonal antibodies

Identifiers

PMID42011880
PMCPMC13367243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.